Evidence map›Paper›PMID 26318425›Full record

ArticleOncotarget2015

RFPL3 and CBP synergistically upregulate hTERT activity and promote lung cancer growth.

Yu Qin, Wangbing Chen, Yao Xiao, Wendan Yu, Xin Cai, Meng Dai, Tingting Xu, Wenlin Huang, Wei Guo, Wuguo Deng and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Yu QinThe First Affiliated Hospital and Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Wangbing ChenSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Yao XiaoThe First Affiliated Hospital and Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Wendan YuThe First Affiliated Hospital and Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Xin CaiThe First Affiliated Hospital and Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Meng DaiThe First Affiliated Hospital and Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Tingting XuThe First Affiliated Hospital and Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Wenlin HuangSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Wei GuoThe First Affiliated Hospital and Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Wuguo DengSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Taihua WuThe First Affiliated Hospital and Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Dalian Medical University · CNFirst Affiliated Hospital of Dalian Medical University · CNState Key Laboratory of Oncology in South ChinaSun Yat-sen University · CNSun Yat-sen University Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

hTERT is the key component of telomerase and its overactivation contributes to maintaining telomere length and cell immortalization. Previously, we identified RFPL3 as a new transcription activator of hTERT in lung cancers. However, the exact mechanism of RFPL3 in mediating hTERT activation and its associated signal regulatory network remain unclear. In this study, we found that RFPL3 colocalized and interacted directly with CBP in the nucleus of lung cancer cells. Immunohistochemical analysis of tissue microarrays of lung cancers revealed the simultaneous overexpression of both RFPL3 and CBP predicted relatively poor prognosis. Furthermore, we confirmed their synergistic stimulation on hTERT expression and tumor cell growth. The binding of RFPL3 to hTERT promoter was reduced markedly when CBP was knocked down by its specific siRNA or suppressed by its inhibitor in lung cancer cells with stable overexpression of RFPL3. When one of the two proteins RFPL3 and CBP was upregulated or downregulated, whereas the another remains unchanged, hTERT expression and telomerase activity were activated or repressed accordingly. In the meantime, the growth of lung cancer cells was also promoted or attenuated accordingly. Furthermore, we also found that RFPL3 coordinated with CBP to upregulate hTERT through the CBP-induced acetylation of RFPL3 protein and their co-anchoring at hTERT promoter region. Collectively, our results reveal a new mechanism of hTERT regulation in lung cancer cells and suggest the RFPL3/CBP/hTERT signaling pathway may be a new targets for lung cancer treatment.

Indexed as

AdenocarcinomaAgedCarcinoma, Non-Small-Cell LungCarrier ProteinsCell Line, TumorCell ProliferationCell SurvivalFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansImmunohistochemistryLung NeoplasmsMaleMicroscopy, FluorescenceMiddle Agedbone sialoprotein (35-62), humanCarrier ProteinsPeptide FragmentsRFPL3 protein, humanRNA, Small InterferingSialoglycoproteinsTelomeraseTERT protein, humanCBPhTERTlung cancerRFPL3

Identifiers

PMID26318425
PMCPMC4694978
OpenAlexW1826984308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.